Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are responsible for the development of metastatic disease, and may also hold the key to determining tailored therapies of advanced cancer disease. Our review summarizes the prognostic significance of the detection of CTCs and DTCs in various gastrointestinal cancers with an overview of their possible use as prognostic biomarkers. This could be used in the future as a starting point for new clinical trials focusing on the predictive potential of circulating and disseminated tumor cells. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 265-277) Key words: circulating tumor cells; gastrointestinal cancer; esophageal cancer; colorectal cancer; gastric cancer; plastin3; prognosis Abbreviations AFP -alpha fetoprotein; BM -bone marrow; CD -cluster of differentiation; CEA -carcinoembryonic antigen; CHT -chemotherapy; CI -confidence interval; CTC -circulating tumor cell; CRCcolorectal carcinoma; CVB -central venous blood; CK -cytokeratin; DAPI -4,6-diamidino-2-phenylindole; DFS -disease free survival; DTC -disseminated tumor cell; EpCAM -epithelial cell adhesion molecule; FISH -fluorescent in situ hybridization; 5-FU -5-fluorouracil; HCC -hepatocellular carcinoma; HR -hazard ratio; ISET -isolation by size of epithelial tumor; ITC -isolated tumor cells; MACS -magnetic activated cell sorting; MFS -metastasis free survival; MSP -methylation specific polymerase chain reaction; MVB -mesenteric venous blood; NA -not available; OS -overall survival; PB -peripheral blood; PFS -progression-free survival; qPCR -quantitative real-time polymerase chain reaction; RFA -radiofrequency ablation; RT -radiotherapy; RT-PCR -reverse transcription polymerase chain reaction; TGFb1 -transforming growth factor b1; TRC method -transcription reverse-transcription concerted method
Introduction
Single tumor cells occurring in blood circulation are called circulating tumor cells (CTCs), while the single tumor cells seeding distant organs prior to detection of metastasis are termed DTCs (disseminated tumor cells) [1] . CTCs and DTCs are believed to be responsible for the development of metastatic disease, as shown in the parallel-progression model of metastatic cascade [1, 2] .
Over the last decade, various methods and systems have been developed to isolate and characterize CTCs and DTCs. The presence of these cells accompanies tumor invasion through the bloodstream and dissemination into other distant sites. Much effort has been necessary to understand the biology of cancer dissemination and to make clinical use of CTCs and DTCs. 
A cancer cell in circulation: a rare event
Recently, our understanding of cancer has considerably improved. While the basic definition of cancer remains unchanged, it is now considered a complex disease. CTCs and DTCs may be rare events of primary tumor progression. Many clinical studies have been conducted showing the utility of CTC detection in the peripheral blood as a valuable predictor of the clinical outcome for patients with solid tumors [3] [4] [5] . Detection, monitoring, and molecular analysis of these extremely rare cancer cells (estimated as one tumor cell per billion normal blood cells in patients with diagnosed metastatic cancer) could provide new possibilities in cancer treatment [6] .
The methodology used for CTCs studies in gastrointestinal cancer has been reviewed in depth by Negin et al. [6] . There is no doubt that the development of new more sensitive detection techniques is crucial, and is aimed at gaining higher counts of CTCs and DTCs to make these methods into powerful tools of prediction. We have tried to produce a useful overview of recent methods of detection, isolation, and characterization of CTCs, such as immunomagnetic separation, flow cytometry, fluorescent in situ hybridization (FISH), and reverse transcription polymerase chain reaction (RT-PCR).
Nowadays, the only predictive marker used in colorectal carcinoma (CRC) is the KRAS gene, tested by gene mutational analysis. It is believed that we are close to discovering other genes for predictive purposes. This can also be achieved using CTCs, but their counts seem currently to be insufficient for proper analysis. CTC counts in analyzed peripheral blood in gastrointestinal cancers (e.g., esophageal and gastric cancer), are low compared with other malignancies such as breast and prostate cancer. The absolute numbers in gastrointestinal cancers (such as metastatic colorectal cancer) are reported as 1-2 CTCs/7.5 mL of blood, while in metastatic prostate and breast cancer, counts are on the level of 3-5 and 6-7 CTCs/7.5 mL of blood, respectively [7] [8] [9] [10] . It has been discussed that that liver could filter the blood coming in from the peritoneum, so CTCs may remain in the liver and occupy hepatic tissue, developing local metastasis [6] . This could be the reason that significantly higher rates of CTCs can be found analyzing mesenteric venous blood (MVB) in comparison to the peripheral blood [11] . This fact should be reflected in clinical studies, where perioperative blood sampling might be a source of CTCs for predictive analysis.
The range of possible diagnostic and therapeutic uses of CTCs is very wide. Firstly, monitoring cancer disease and demonstrating the therapeutic success achieved by molecular testing of CTCs (which in future may be known as 'liquid biopsy') are possible applications. Secondly, useful methods for inoperable patients where there is no other possibility of obtaining information about the tumor character (which could be called 'real-time tumor biopsy') is another option. In addition, it seems that CTCs and DTCs could provide a very good source of information about the chemosensitivity and chemoresistance of the primary tumor and about distant sites of metastasis [12] .
However, very little is still known about the exact number of tumor cells released into the bloodstream by tumors in humans. It is hypothesized that 1 g of primary tumor may release 10 6 cells into the bloodstream every 24 hours [13] . It has been shown in orthotopic metastatic tumor animal models that surgical manipulation during oncological procedures may enhance the release of cancer cells from the primary tumor site into the circulation. Pressure, biopsy, and laser treatments can all dramatically increase CTC counts (up to sixty-fold), whereas proper tumor resection significantly decreases CTC count [14] . Similarly, increases in CTC counts have been show in human clinical studies of radiofrequency ablation (RFA) -a method of tissue destruction that uses the heat generated by high-frequency alternating current. CTCs from patients with CRC liver metastases were quantified prior to and immediately after open surgery, laparoscopic resection, and open or percutaneous RFA. Surgical procedures led to a statistically significant decrease in CTC counts measured at multiple sites (peripheral vein and artery, hepatic portal vein, hepatic vein). Conversely, RFA, whether open or percutaneous, was associated with a significant increase in CTC count [15] . It may be expected that in vivo detection of intervention-amplified CTCs could be used in the future for early diagnosis of small tumors undetectable with conventional methods [14] .
Clinical impact of CTCs in clinical studies in patients with esophageal, gastric, and colorectal cancer
The clinical relevance of CTC analysis in gastrointestinal cancers is summarized in Tables 1-4 , in which studies are listed according to the diagnosis and the CTC detection method. CHT, CK, CTC, DFS, DTC, GC, Mets, NA, OS -same as described for Table 1 . BIRCs -BIR-containing proteins; CEA -carcinoembryonic antigen; CEACAM5 -carcinoembryonic antigen-related cell adhesion molecule 5; CRC -colorectal cancer; DAPK -death-associated protein kinase; ESCC -esophageal squamous cell carcinoma; EpCAM -epithelial cell adhesion molecule; ERBB2 -erythroblastic leukemia viral oncogene homolog 2; ERCC1 -excision repair cross-complementing 1 protein; MSP -methylation specific polymerase chain reaction; MUC1 -mucin 1; PC -pancreatic cancer; RT-PCR -reverse transcription polymerase chain reaction; SCGB2A2 -secretoglobin family 2A member 2. Table 4 .
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Esophageal cancer (EC)
Esophageal cancer (EC) is notorious for its aggressive biological behavior, local infiltration, involvement of adjacent lymph nodes, and broad metastasis through hematogenous spread. It has been reported that the frequency of hematogenous recurrence is high, despite radical surgery with lymph node dissection [16] . In this regard, the detection of cancer cells in the blood could be important for identifying patients with a high risk of relapse. There have been many studies showing a positive correlation between detection of CTCs, tumor staging, and patient prognosis. Detection of CTCs from PB of EC patients by conventional qPCR methods has been reported for several genes. Liu et al. [17] aimed at establishing a quantitative system for evaluating the role of CTCs in PB from patients who underwent surgical resection during esophageal cancer treatment. 155 PB samples from 53 EC patients were collected before surgery (B-1), immediately after surgery (B0), and on the third postoperative day (B+3). A direct qPCR method based on CEA mRNA gene expression was designed for the detection of CTCs. The authors showed significant differences between groups B-1 vs. B0 (p = 0.0001) and B-1 vs. B+3 (p = 0.0209). 50% of the patients with R > 0.4 (R = CTC ratio of B+3 over B0) showed tumor recurrence within 1 year after surgery, whereas the probability was only 14.3% for patients with R < 0.4 (p = 0.043). The prognostic utility of CTCs in EC has been shown also in studies where the gene expression of survivin, ERCC1, and APC has been tested by RT-PCR, as shown in Table 2 .
The prognostic relevance of the presence of DTCs in bone marrow (BM) for the postoperative course of EC has also been evaluated recently [18] : 370 patients with EC diagnosis (189 squamous cell carcinomas and 181 adenocarcinomas), were surgically treated with complete resection (R0). They received neither adjuvant nor neoadjuvant therapy. DTCs were detected by an immunocytochemical cytokeratin assay in preoperatively taken BM aspirates. Overall, 120 (32.4%) patients harbored DTCs in their BM. The presence of DTCs significantly correlated with aggressive tumor biology, as indicated by increased tumor size (p = 0.026), regional (p = 0.002) and distant (p = 0.012) lymph node metastases, and higher relapse rate (p < 0.001, c 2 test). The presence of DTCs in bone marrow was a very strong and independent prognostic factor in patients with resectable EC [18] .
The CTC status in the PB of patients with esophageal squamous cell carcinoma (ESCC), before and after radiotherapy (RT), was evaluated by Yin et al. [19] . A total of 72 ESCC patients enrolled in this study were treated with radical RT. The nested RT-PCR reaction was used to detect the three representative markers of CTCs: CEA, CK19, and survivin. The results showed that the presence of CTCs, and the positive expression of at least one of these three markers in patients with ESCC pre-RT and post-RT were 54.2% and 38.9%, respectively (p = 0.059). Furthermore, the analysis of the patients according to lymph node metastasis and adverse 2-year progression -free survival (PFS) revealed changes in CTC status after RT, which would reflect patients' response to RT. In a multivariate analysis with the Cox proportional hazard model, only CTC positivity post-RT was an independent, unfavorable prognostic factor for ESCC, apart from subsequent chemotherapy and patients' Karnofsky performance status scores (a scale quantifying cancer patients' general well-being). In conclusion, the positive detection of CTCs in patients with ESCC after RT may be a promising biomarker for radiation efficiency and prognosis assessment in ESCC [19] .
Gastric cancer (GC)
Follow-up studies on gastric cancer (GC) patients suggested that CTC-positive cases with increased burdens of CTCs were associated with poorer prognoses than CTC-negative cases. The situation was similar with DTCs [15] . Both localized and metastatic GC can shed detectable concentrations of CTCs into the blood. The presence of CTCs in circulation suggests not only a high risk of tumor recurrence, but also an unfavorable clinical outcome even in the early stages of GC [20] . The prognostic impact of CTCs in GC has been reported in several studies [21] [22] [23] [24] [25] [26] [27] . The sensitivity of RT-PCR CTC detection was superior to the other less commonly used cytological detection methods involving fluorescence-activated cell sorting (FACS), immunohistochemistry (IHC), and immunocytochemistry (ICC) [20] . For the identification of CTCs in GC, different markers and their combinations were tested in the analyzed studies. The combination of EpCAM, CK8, CK18, and CK19 seems to be prognostically the most relevant in GC [7, 24] . On the other side, single survivin expression also achieved prognostic significance in at least 2 studies [29, 30] . Based on the analyzed data, detection of CTCs might be used as a noninvasive method, not only for the confirmation of GC diagnosis, but also for estimation of prognosis.
Colorectal cancer (CRC)
In general, the detection of CTCs in colorectal cancer (CRC), independently of the method and markers [31, 32] . On the other side, the correlation of CTCs with some known clinicopathological prognostic factors (e.g., T4 tumor size, perineural invasion, bowel obstruction, high preoperative CEA levels) is still uncertain [32] . It is believed that the correlation of CTCs with clinicopathological factors would increase if the sensitivity of the CTC detection were higher. CTC positivity is observed in approximately 40-50% of metastatic CRC patients. Differences in CTCs detection can be observed depending on the sampling site, as shown by Rahbari et al. [10] , who tested compartmental differences of CTC in CRC. The qualitative and quantitative detection of CTCs was higher in the mesenteric venous blood (MVB) than in the central venous blood (CVB) of patients with CRC. It has been speculated that the liver works as a filter and stops CTCs from entering the central circulation [6] . Moreover, higher counts of CTCs were detected when the tumor was localized in the lower part of rectum than in the cases of middle and high rectal involvement [6, 33] .
The biomarkers used for the CTCs detection in cytological or RT-PCR examination of patients with CRC are listed in Tables 3 and 4 . Generally, the EpCAM pre-enrichment is a basis for further cytokeratine (CK19/20, CK8/18) and CEA testing. Recently, plastin3 has been shown to have significant clinical relevance. Plastin3 positivity in the PB was found to be associated with clinicopathological risk factors, such as depth of invasion, lymph node and liver metastasis, presence of peritoneal dissemination, increased recurrence rate, and higher Dukes stage. It is very important to note that plastin3 expression was also detected in all patients with recurrent disease, and at a level higher than in the case of prerecurrence and of patients without recurrence [34] . The correlation between CTCs and prognosis in CRCs was stronger if CKs and multiple markers were used than for the one-marker assay [35] .
Recently, several meta-analyses evaluating the prognostic value of CTC examination in CRC have been published. Rahbari et al. [36] included 36 studies and 3094 patients in their final meta-analysis. The pooled analyses combining all sampling sites (PB, mesenteric PB (MPB), and BM) associated the detection of CTCs/DTCs with poor recurrence-free survival (RFS). Stratification by sampling site showed that detection of CTCs in the PB compartment was a statistically significant prognostic factor, but that detection in the MPB or BM was not.
Similarly, 12 studies representing 1329 patients were suitable for pooled analysis of CRC patients in a prognostic study [37] . The OS and PFS were worse in CTC-positive patients, whereas analyzing PFS separately, the subgroup with significantly worse survival rate contained over 35% CTC-positive patients. Multivariate analysis was performed on eight studies and identified the detection of CTCs as an independent prognostic factor for survival. Moreover, the meta-analysis reported that the detection of CTCs in PB of patients with resectable colorectal liver metastases, or with widespread metastatic CRC, was associated with disease progression and poor survival [37] . The study of Katsuno et al. [38] highlights the potential importance of cancer cell detection in the venous drainage of colorectal cancers as a prognostic marker and a mode of staging in this neoplastic disease.
Regarding the effect of chemotherapy on CTC counts, it has been evaluated that the prognosis of patients with undetectable CTCs after chemotherapy was significantly better [39] . Additionally, molecular detection of persistent postoperative CTCs has been confirmed as a prognostic marker of early relapse in I-III stage CRC patients, which could help to select patients for an enhanced follow-up and therapeutic program [40, 41] .
In summary, it is expected that CTCs and DTCs will be used for mutational analysis of the genes connected directly to the targeted therapy (e.g., KRAS, BRAF). The heterogeneity of the genetic profiles of cells from the primary tumor, metastatic tumors, and CTCs may be an explanation for the variable response to EGFR-inhibitor chemotherapy [5, 42, 43] . CTCs are not only a marker for advanced disease, but also have prognostic and predictive potential. A decrease in CTC levels during chemotherapy is correlated with improved responses to chemotherapy [39] .
Several very important questions need to be answered, and further studies are required to unify the isolation techniques before CTCs can be adapted for widespread clinical use. In particular, the following questions should be central to future research: Can CTCs be used to define a group of patients with "resectable" metastases who should not undergo resection? Can CTCs be used to monitor the immediate effectiveness of systemic chemotherapy or to predict which chemotherapy would be most effective? Can CTCs be used to help staging patients with metastatic CRCs?
Finally, we are reminded that stage IV of colorectal cancer is a disease with many possible outcomes, ranging from rapid death to recovery [40] . We also recall that our ability to predict which patient will experience which outcome is relatively limited. The detection of CTCs is a potentially promising biomarker that could contribute to the staging of the cancer and this deserves a prospective study. 
Conclusion
In summary, it is essential to establish sensitive, specific technologies to detect CTCs. More detailed analyses of their molecular characteristics should be performed with the aim of understanding the biology of CTCs and DTCs. This may provide a yet-untapped option to develop therapeutic strategies that will effectively treat and prevent metastatic process for each person individually.
